0001209191-19-052754.txt : 20191008
0001209191-19-052754.hdr.sgml : 20191008
20191008162520
ACCESSION NUMBER: 0001209191-19-052754
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191006
FILED AS OF DATE: 20191008
DATE AS OF CHANGE: 20191008
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Clayman Michael D.
CENTRAL INDEX KEY: 0001597407
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36287
FILM NUMBER: 191142906
MAIL ADDRESS:
STREET 1: C/O FLEXION THERAPEUTICS, INC.
STREET 2: 10 MALL ROAD, SUITE 301
CITY: BURLINGTON
STATE: MA
ZIP: 01803
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Flexion Therapeutics Inc
CENTRAL INDEX KEY: 0001419600
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10 MALL ROAD
STREET 2: SUITE 301
CITY: BURLINGTON
STATE: MA
ZIP: 01803
BUSINESS PHONE: (781) 305-7777
MAIL ADDRESS:
STREET 1: 10 MALL ROAD
STREET 2: SUITE 301
CITY: BURLINGTON
STATE: MA
ZIP: 01803
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-10-06
0
0001419600
Flexion Therapeutics Inc
FLXN
0001597407
Clayman Michael D.
C/O FLEXION THERAPEUTICS, INC.
10 MALL ROAD, SUITE 301
BURLINGTON
MA
01803
1
1
0
0
President and CEO
Common Stock
2019-10-06
4
M
0
14800
A
87049
D
Common Stock
2019-10-07
4
F
0
4402
13.98
D
82647
D
Common Stock
320494
I
By the Michael D. Clayman 2006 Revocable Trust
Common Stock
24600
I
By the Michael D. Clayman Irrevocable Trust
Common Stock
388683
I
By Versant Development Fund III, LLC
Restricted Stock Unit Award
2019-10-06
4
M
0
14800
0.00
D
2019-10-06
Common Stock
14800
0
D
Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
Shares held by Versant Development Fund III, LLC. The Reporting Person is a manager and minority member of Versant Development Fund III, LLC. The Reporting Person disclaims any beneficial ownership of the shares held by Versant Development Fund III, LLC except to the extent of his pecuniary interest in these shares.
On January 4, 2016, the reporting person was granted up to 66,600 restricted stock units. The amount and vesting of the shares under the restricted stock unit award was based on the achievement of certain milestones that were established at the time of the Compensation Committee's approval of the restricted stock unit award on December 17, 2015. On October 6, 2017, the Compensation Committee certified the achievement of a milestone under the restricted stock unit award resulting in the commencement of vesting of 44,400 shares as follows: 14,800 shares vested as of October 6, 2017, 14,800 shares vested as of October 6, 2018 and 14,800 shares vested as of October 6, 2019.
/s/ Mark S. Levine, Attorney-in-Fact
2019-10-08